BELLUS Health is developing drugs for rare diseases with an initial focus on kidney disorders. The Company's lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often rapidly leads to dialysis and death.
BELLUS Health is also developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ has recently completed a Phase II clinical trial.
In addition, the Company is developing a research-stage project for the treatment of AL amyloidosis, which is a rare disease where proteins build up in various parts of the body, mainly in the kidneys, heart, liver and peripheral nerves.